In the same study, a noteworthy finding indicated that a 10 pg/mL reduction in plasma NT-proBNP over an initial 2 years of intervention was associated with a 1% relative decline in the primary composite outcomes, including cardiovascular mortality, myocardial infarction (MI), revascularization procedures, stroke, and amputations [45]. This evidence concerns the gene NPPB and myocardial infarction.